MedPath

PERFECT Project - Part 2 - Study 2

Not Applicable
Completed
Conditions
Obesity Prevention
Diabetes Prevention
Interventions
Other: Pea Starch
Other: Pea fibre + pea starch + pea protein
Other: Control
Other: Pea fibre + pea starch
Other: Pea protein + pea starch
Other: Pea protein
Registration Number
NCT02370927
Lead Sponsor
University of Manitoba
Brief Summary

The objectives are to test the acute effects of different cereals containing pulse ingredients on: 1) aerobic endurance and substrate oxidation during exercise 2) response of blood glucose, insulin and appetite to an aerobic exercise session, and 3) food intake two hours following the exercise session. The investigators hypothesize that consumption of cereals containing pulse ingredients 60 minutes before exercise will increase aerobic endurance (lower oxygen consumption), decrease carbohydrate oxidation (greater respiratory quotient), and a reduction in lactate production during compared to the same exercise session following the ingestion of a non-pulse food. The investigators also hypothesize that consumption of cereals containing pulse ingredients will lead to lower blood glucose, insulin, appetite and food intake, suggesting lower calorie compensation, following a 60-minute aerobic exercise session compared to the same exercise session following the ingestion of a non-pulse food.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Normoglycemic (<5.6 mmol/L) and normotensive (systolic blood pressure <140 mm Hg and diastolic blood pressure below < 90 mm Hg)
  • Body Mass Index of 18.5-29.9 kg/m2
Read More
Exclusion Criteria
  • Restrained eaters
  • Regularly skip breakfast
  • Smokers
  • Those on medications that may influence study outcomes or have experienced any gastrointestinal related health conditions/surgeries over the past year
  • Those who are active (organized activities or athletic training at a high intensity; ≥ 150 minutes per week of moderate to vigorous physical activity)
  • Those unable to walk for an hour continuously
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Cereal w/ pea starchPea StarchPea starch
Cereal w/ pea protein + pea fibre + pea starch:Pea fibre + pea starch + pea proteinPea protein + pea fibre + pea starch: 20g
ControlControl100% Wheat Flour
Cereal w/ pea starch + pea fibrePea fibre + pea starchPea starch + pea fibre: 5g
Cereal w/ pea protein + pea starchPea protein + pea starchPea protein + pea starch: 10g
Cereal w/ pea proteinPea proteinPea protein
Primary Outcome Measures
NameTimeMethod
Food Intakeat 240 minutes

Ad-libitum meal

Exercise intensity60-120 minutes

Oxygen consumption measured during exercise at 3 time points

Insulin concentrations0-240 minutes

Measured in blood using intravenous catheter. and Insulin will be measured by commercially available radioimmunoassay (RIA) kits

Plasma Glucose Concentrations0-240 minutes

Measured in blood using intravenous catheter. Glucose will be determined by automated methods using Abbot Spectrum Clinical Chemistry-X Analyzer,

Subjective Appetite0-240 minutes

Motivation-to-eat Visual Analog Scale questionnaire

Secondary Outcome Measures
NameTimeMethod
Heart rate60-120 minutes

To monitor exercise intensity and give a measure of fatigue (cardiovascular drift)

Palatability measured by Visual Analog Scale questionnaire5 and 260 minutes

Food tasting

Energy/fatigue measured by Visual Analog Scale questionnaire0 - 240 minutes

Estimate of energy expenditure

Lactate concentration60-120 minutes

Measured before, during, and after exercise exercise at 3 time points

Physical comfort measured by Visual Analog Scale questionnaire0-240 minutes

Contributions from energy intake

Substrate Oxidation60-120 minutes

Respiratory quotient measured during exercise at 3 time points

Trial Locations

Locations (1)

Richardson Centre for Functional Foods and Nutraceuticals

🇨🇦

Winnipeg, Manitoba, Canada

© Copyright 2025. All Rights Reserved by MedPath